CN Patent

CN116848238A — 大环补体因子b抑制剂

Assigned to Alexion Pharmaceuticals Inc · Expires 2023-10-03 · 3y expired

What this patent protects

本披露涉及化合物、包含化合物的药物组合物、以及使用这些化合物和组合物治疗与补体级联途径失调相关的疾病或障碍的方法。更特别地，本披露涉及大环化合物及其药物组合物、用这些化合物抑制补体因子B(CFB)表达的方法、以及治疗由CFB介导的疾病或障碍的方法。

USPTO Abstract

本披露涉及化合物、包含化合物的药物组合物、以及使用这些化合物和组合物治疗与补体级联途径失调相关的疾病或障碍的方法。更特别地，本披露涉及大环化合物及其药物组合物、用这些化合物抑制补体因子B(CFB)表达的方法、以及治疗由CFB介导的疾病或障碍的方法。

Drugs covered by this patent

iptacopan-hydrochloride (IPTACOPAN HYDROCHLORIDE)

Patent Metadata

Patent number: CN116848238A
Jurisdiction: CN
Classification: —
Expires: 2023-10-03
Drug substance claim: No
Drug product claim: No
Assignee: Alexion Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.